Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Int J Mol Sci ; 21(8)2020 Apr 16.
Article in English | MEDLINE | ID: mdl-32316353

ABSTRACT

Cell-based approaches of cartilage lesions use different culture systems to obtain optimal cell quality. Pellet cultures with high cellular density (HD) are the gold standard to keep chondrocytes in a differentiated stage. Bacterial cellulose (BC) hydrogel is discussed to prevent cellular aging and dedifferentiation. The hypothesis of this study was that HD culture on BC hydrogel (HD hydrogel) might reach the chondrogenic potential of pellet culture (pellet). Human articular osteoarthritic (OA) and non-osteoarthritic (non-OA) chondrocytes were cultured for seven days within pellets and compared to HD hydrogel and HD polystyrene. Gene expression analysis and histological assessment were performed. We observed no significant change of COL2A1 expression by the culture system (pellet, HD hydrogel and HD polystyrene) but a significant change of COL2A1/COL1A1-ratio, with the highest ratio in pellets. Chondrocytes on HD hydrogel showed an elevated expression of MMP13 and on polystyrene an increased expression of COL1A1 and MMP13. The patterns of gene expression changes observed in OA and non-OA chondrocytes in reaction to the different culture systems were similar in those two cell groups. Pellet cultures moreover formed a histomorphologically superior neocartilage. Concluding, human chondrocytes kept the potential to express COL2A1 in all HD culture systems. However, pellets excelled in a higher COL2A1/COL1A1-ratio, a higher extracellular matrix deposit and in not developing degeneration and dedifferentiation markers. This underlines the superiority of pellet culture in maintaining the chondrogenic potential of human chondrocytes in vitro.


Subject(s)
Cell Culture Techniques/methods , Hydrogels/chemistry , Aggrecans/genetics , Aggrecans/metabolism , Cells, Cultured , Cellulose/chemistry , Chondrocytes/cytology , Chondrocytes/metabolism , Chondrocytes/pathology , Collagen Type I/genetics , Collagen Type I/metabolism , Collagen Type I, alpha 1 Chain , Collagen Type II/genetics , Collagen Type II/metabolism , Gene Expression , Gluconacetobacter/metabolism , Humans , Matrix Metalloproteinase 13/genetics , Matrix Metalloproteinase 13/metabolism , Polystyrenes/chemistry , SOX9 Transcription Factor/genetics , SOX9 Transcription Factor/metabolism
2.
BMC Complement Altern Med ; 17(1): 402, 2017 Aug 14.
Article in English | MEDLINE | ID: mdl-28806939

ABSTRACT

BACKGROUND: Studies of the effects of electromagnetic fields (EMFs) on cartilaginous cells show a broad range of outcomes. However EMFs are not yet clinically applied as standard treatment of osteoarthritis, as EMF effects are showing varying outcomes in the literature. The aim of this study was to examine effects of EMFs (5 mT or 8 mT) on osteoarthritic (OA) and non-OA chondrocytes in order to investigate whether EMF effects are related to chondrocyte and EMF quality. METHODS: Pellets of human OA and non-OA chondrocytes were exposed to a sinusoidal 15 Hz EMF produced by a solenoid. Control groups were cultivated without EMF under standard conditions for 7 days. Cultures were examined by staining, immunohistochemistry and quantitative real-time PCR for RNA corresponding to cartilage specific proteins (COL2A1, ACAN, SOX9). RESULTS: OA chondrocytes increased the expression of COL2A1 and ACAN under 5 mT EMF compared to control. In contrast no changes in gene expression were observed in non-OA chondrocytes. OA and non-OA chondrocytes showed no significant changes in gene expression under 8 mT EMF. CONCLUSION: A 5 mT EMF increased the expression of cartilage specific genes in OA chondrocytes whereas in non-OA chondrocytes no changes in gene expression were observed. An 8 mT EMF however showed no effect altogether. This suggests that EMF effects are related to EMF but also to chondrocyte quality. Further studies about the clinical relevance of this effect are necessary.


Subject(s)
Aggrecans/metabolism , Cartilage, Articular/cytology , Chondrocytes , Collagen Type II/metabolism , Electromagnetic Fields , Osteoarthritis , Cells, Cultured , Gene Expression , Humans , Immunohistochemistry , Magnetic Field Therapy , Osteoarthritis/metabolism , Osteoarthritis/therapy , Real-Time Polymerase Chain Reaction
3.
Int Orthop ; 38(12): 2615-21, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25030964

ABSTRACT

PURPOSE: During in vitro chondrogenesis of human mesenchymal stem cells (hMSCs) hypertrophy is an inadvertent event associated with cell differentiation toward the osteogenic lineage. Up to now, there is no stringent experimental control mechanism to prevent hypertrophy of MSCs. Microgravity is known to have an impact on osteogenesis. In this study, the influence of simulated microgravity (SMG) on both chondrogenesis and hypertrophy of hMSCs was evaluated. METHODS: A bioreactor using a rotating wall vessel was constructed to simulate microgravity. Pellet cultures formed from hMSCs (P5) were supplemented with human transforming growth factor-ß3 (TGF-ß3). The hMSC pellet cultures treated with TGF-ß3 were either kept in SMG or in a control system. After three weeks of culture, the chondrogenic differentiation status and level of hypertrophy were examined by safranin-O staining, immunohistochemistry and quantitative real-time PCR. RESULTS: SMG reduced the staining for safranin-O and collagen type II. The expression of collagen type X α1 chain (COL10A1) and collagen type II α1 chain (COL2A1) were both significantly reduced. There was a higher decrease in COL2A1 than in COL10A1 expression, resulting in a low COL2A1/COL10A1 ratio. CONCLUSIONS: SMG reduced hypertrophy of hMSCs during chondrogenic differentiation. However, the expression of COL2A1 was likewise reduced. Even more, the COL2A1/COL10A1 ratio decreased under SMG conditions. We therefore assume that SMG has a significant impact on the chondrogenic differentiation of hMSCs. However, due to the high COL2A1 suppression under SMG, this culture system does not yet seem to be suitable for a potential application in cartilage repair.


Subject(s)
Chondrogenesis/physiology , Mesenchymal Stem Cells/pathology , Weightlessness Simulation , Aggrecans/metabolism , Cell Differentiation , Collagen Type II/metabolism , Collagen Type X/metabolism , Humans , Hypertrophy , Immunohistochemistry , Mesenchymal Stem Cells/cytology , Osteogenesis , Real-Time Polymerase Chain Reaction
4.
Tissue Eng Part A ; 16(3): 1093-101, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20035609

ABSTRACT

The repair of bone defects can be induced experimentally with bone morphogenetic protein-2 (BMP-2) producing fat-derived stem cells, but this ex vivo tissue engineering method requires the isolation and long-term culture of autologous cells. To develop an expedited bone repair strategy, we transferred BMP-2 cDNA directly to autologous fat tissue fragments that were held in culture for only 24 h before implantation. We evaluated the ability of such gene-activated fat grafts to regenerate large segmental bone defects in rats. Fat tissue was harvested from 2 of 35 male Fischer 344 rats used for this study. The fat tissue fragments were incubated with an adenoviral vector carrying the cDNA encoding either BMP-2 or green florescent protein (GFP), or they remained unmodified. According to their group, the segmental femoral bone defects of 33 rats were filled press fit with either BMP-2-activated fat tissue, GFP-transduced fat tissue, or unmodified fat tissue. Another control group remained untreated. Femora were evaluated by radiographs, microcomputed tomography, biomechanical torsional testing, and histology. Radiographically and histologically, 100% of the femora treated with BMP-2-activated fat grafts were bridged at 6 weeks after surgery. The femora of this group exceeded the bone volume and the biomechanical stability of intact, contralateral femora. Control defects receiving no treatment, unmodified fat tissue, or GFP-transduced fat were filled with fibrous or adipose tissue, as evaluated by histology. The use of BMP-2 gene-activated fat tissue grafts represents an expedited and effective bone repair strategy that does not require the extraction and expansion of stem cells.


Subject(s)
Adipose Tissue/metabolism , Bone Morphogenetic Protein 2/genetics , Femur/pathology , Implants, Experimental , Transcriptional Activation , Adipose Tissue/transplantation , Animals , Biomechanical Phenomena , Bone Morphogenetic Protein 2/metabolism , Enzyme-Linked Immunosorbent Assay , Femur/diagnostic imaging , Green Fluorescent Proteins/metabolism , Male , Organ Size , Rats , Rats, Inbred F344 , Torque , Transduction, Genetic , Wound Healing , X-Ray Microtomography
5.
Hum Gene Ther ; 20(12): 1589-96, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19572783

ABSTRACT

Numerous preclinical studies have shown that osseous defects can be repaired by implanting bone morphogenetic protein (BMP)-2-transduced muscle cells. However, the drawback of this treatment modality is that it requires the isolation and long-term (approximately 3 weeks) culture of transduced autologous cells, which makes this approach cumbersome, time-consuming, and expensive. Therefore, we transferred BMP-2 cDNA directly to muscle tissue fragments that were held in culture for only 24 hr before implantation. We evaluated the ability of such gene-activated muscle grafts to induce bone repair. Two of 35 male, syngeneic Fischer 344 rats used in this study served as donors for muscle tissue. The muscle fragments remained unmodified or were incubated with an adenoviral vector carrying the cDNA encoding either green fluorescent protein (GFP) or BMP-2. Critical-size defects were created in the right femora of 33 rats and remained untreated or were filled (press fitted) with either unmodified muscle tissue or GFP-transduced muscle tissue or with BMP-2-activated muscle tissue. After 6 weeks, femora were evaluated by radiography, microcomputed tomography (muCT), histology, and biomechanical testing. Six weeks after implantation of BMP-2-activated muscle grafts, 100% of the bone defects were bridged, as documented by radiographs and muCT imaging, and showed formation of a neocortex, as evaluated by histology. Bone volumes of the femora repaired by BMP-2-transduced muscle were significantly (p = 0.006) higher compared with those of intact femora and the biomechanical stability was statistically indistinguishable. In contrast, control defects receiving no treatment, unmodified muscle, or GFP-transduced muscle did not heal. BMP-2 gene-activated muscle grafts are osteoregenerative composites that provide an expedited means of treating and subsequently healing large segmental bone defects.


Subject(s)
Bone Morphogenetic Protein 2/genetics , Bone Regeneration , Fracture Healing , Genetic Therapy/methods , Muscle, Skeletal/transplantation , Animals , Cell Culture Techniques , Cells, Cultured , DNA, Complementary/genetics , Femur/diagnostic imaging , Femur/injuries , Genetic Vectors/genetics , Green Fluorescent Proteins/genetics , Male , Muscle, Skeletal/cytology , Muscle, Skeletal/metabolism , Radiography , Rats , Rats, Inbred F344 , Recombinant Proteins/genetics , Transduction, Genetic/methods , Transplantation, Isogeneic
6.
Front Biosci ; 13: 5195-201, 2008 May 01.
Article in English | MEDLINE | ID: mdl-18508581

ABSTRACT

Epithelial cell adhesion molecule EpCAM is strongly over-expressed in a variety of carcinomas where it is involved in signalling events resulting in increased expression of target genes such as c-Myc, cyclins and others, eventually conferring cells an oncogenic phenotype. However, EpCAM is also expressed in a series of healthy epithelia, albeit generally to a far lesser extend. We have uncovered differential glycosylation of EpCAM as a means to discriminate normal from malignant tissues. EpCAM was hyperglycosylated in carcinoma tissue as compared with autologous normal epithelia. All three N-glycosylation consensus sequences within EpCAM's extracellular domain were used in human and murine cells. We show that glycosylation at asparagine198 is crucial for protein stability. Mutants of EpCAM that substitute asparagine198 for alanine showed a decreased overall expression and half-life of the molecule at the plasma membrane. This is of considerable importance with respect to EpCAM variants expressed in normal tissue, where it might reveal to be less stable and thus may have repercussions on functionality.


Subject(s)
Antigens, Neoplasm/metabolism , Cell Adhesion Molecules/metabolism , Neoplasms/physiopathology , 3T3 Cells , Animals , Antigens, Neoplasm/genetics , Asparagine/genetics , Cell Adhesion Molecules/genetics , Cell Line , Epithelial Cell Adhesion Molecule , Glycoside Hydrolases/pharmacology , Glycosylation , Humans , Kidney , Mice , Mutation
7.
Anticancer Res ; 26(1B): 783-9, 2006.
Article in English | MEDLINE | ID: mdl-16739354

ABSTRACT

Serological screening techniques, such as SEREX and AMIDA, use tumour-specific antibodies in the blood of patients to identify tumour-associated antigens. Using AMIDA, we have recently reported the identification of cytokeratin 8 (CK8) as a new tumour antigen and the presence of elevated serum levels of CK8-specific antibodies (CK8-Abs) in patients with head and neck cancer (HNC). The translation of such a biological observation into a reliable biomarker for clinical diagnosis is a major challenge across the border of biological and clinical research. A prerequisite for a valuable biomarker is specificity, ie. its restriction to a defined disease. Whether the serum levels of CK8-Abs are elevated in patients suffering from other diseases besides HNC was evaluated in this study. A panel of 749 serum samples from patients with carcinomas and benign diseases of different localisations, autoimmune diseases and infections, as well as from clinically healthy donors, was tested. In total, 3.2 times more patients with benign disease (16%) and 2.4 times more patients with carcinomas (12%) showed specific CK8 serum reactivity compared to the healthy donors. However, reactivity was not associated with the kind of disease, i.e. malignant or benign disease, but rather with the disease localisation. Thus CK8-Abs on their own do not allow for the detection of carcinoma of a defined localisation or for the differentiation between carcinoma and benign diseases.


Subject(s)
Autoantibodies/immunology , Carcinoma/immunology , Keratins/immunology , Neoplasms/immunology , Adult , Aged , Antibody Specificity , Autoantibodies/blood , Carcinoma/blood , Female , Humans , Male , Middle Aged , Neoplasms/blood
8.
Biochem Biophys Res Commun ; 328(4): 1154-62, 2005 Mar 25.
Article in English | MEDLINE | ID: mdl-15707998

ABSTRACT

We reported the identification of tumour-associated antigens from head and neck carcinomas, including cytokeratin 8 (CK8). These antigens were isolated based on the humoral immune response they elicit in vivo using the antibody-mediated identification of antigens technology. Unlike healthy squamous epithelium, tumour cells displayed CK8 at the plasma membrane. However, the actual presence of CK8 at the plasma membrane is still a matter of debate. Here, we have analyzed the expression of CK8 in detail using confocal laser scanning microscopy and circumstantiated its localization at the plasma membrane of carcinoma cells. Healthy human tissues were devoid of CK8 at the membrane, with the exception of hepatocytes. Moreover, membrane-associated CK8 molecules experienced a re-distribution throughout mitosis, which was associated with phosphorylation at serine 73. Phosphorylated CK8 redistributed into dense speckles and relocated to the plasma membrane upon cytokinesis. Thus, CK8 possesses genuine extracellular epitopes on tumour cells, which may represent valuable targets for therapy.


Subject(s)
Biomarkers, Tumor/metabolism , Cell Membrane/metabolism , Keratins/metabolism , Neoplasms/metabolism , Neoplasms/pathology , Cell Cycle , Cell Line, Tumor , Humans , Organ Specificity , Tissue Distribution
9.
Oncogene ; 23(34): 5748-58, 2004 Jul 29.
Article in English | MEDLINE | ID: mdl-15195135

ABSTRACT

Epithelial cell adhesion molecule (EpCAM) is a membrane glycoprotein expressed on adenomatous and simple epithelia, where it is involved in homophilic adhesion at the basolateral membrane. Carcinomas strongly overexpress EpCAM through an, as yet, unknown mechanism. Interestingly, otherwise EpCAM-negative squamous epithelia are seen to express EpCAM concomitant with their transformation and de-differentiation. The amount of EpCAM and the number of expressing cells both increase with the grade of dysplasia. Despite an important amount of data correlating the expression of EpCAM with cellular proliferation and de-differentiation, such as the coexpression with Ki-67, a marker for proliferation, it is unknown whether EpCAM may directly contribute to carcinogenesis. Here, we show that EpCAM has a direct impact on cell cycle and proliferation, and the ability to rapidly upregulate the proto-oncogene c-myc and cyclin A/E. Human epithelial 293 cells as well as murine NIH3T3 fibroblasts expressing EpCAM had a decreased requirement for growth factors, enhanced metabolic activity and colony formation capacity. Importantly, the inhibition of EpCAM expression with antisense mRNA led to a strong decrease in proliferation and metabolism in human carcinoma cells. Moreover, domain swapping experiments demonstrated that the intracellular part of EpCAM is necessary and sufficient to transduce the effects described. Thus, the data presented here highlight the role of EpCAM, demonstrating for the first time a direct link to cell cycle and proliferation.


Subject(s)
Antigens, Neoplasm/metabolism , Cell Adhesion Molecules/metabolism , Proto-Oncogene Proteins c-myc/genetics , 3T3 Cells/metabolism , 3T3 Cells/pathology , Animals , Antigens, Neoplasm/genetics , Carcinogenicity Tests , Carcinoma/genetics , Carcinoma/metabolism , Carcinoma/pathology , Cell Adhesion Molecules/genetics , Cell Cycle/physiology , Cell Division/physiology , Cells, Cultured , Cyclin A/genetics , Cyclin A/metabolism , Cyclin E/genetics , Cyclin E/metabolism , Epithelial Cell Adhesion Molecule , Epithelial Cells/metabolism , Epithelial Cells/pathology , Gene Expression Regulation , Humans , Mice , Protein Structure, Tertiary , Proto-Oncogene Mas , Proto-Oncogene Proteins c-myc/metabolism , Up-Regulation
10.
Anticancer Res ; 24(2B): 887-93, 2004.
Article in English | MEDLINE | ID: mdl-15161042

ABSTRACT

BACKGROUND: New adjuvant immunological therapies that selectively redirect effector cells towards tumour cells are currently under development. These strategies include the use of bispecific antibodies as promising tools for the elimination of disseminated tumour cells and micrometastases. At present, bispecific molecules have demonstrated their antitumour potential in investigations in vitro using monolayer cell cultures. However, their effectiveness in vivo is less clear and expressive in vitro tumour models are in high demand. MATERIALS AND METHODS: Three-dimensional multicellular tumour spheroids (MTS) are of intermediate complexity between monolayer cell cultures and solid tumours in patients and therefore represent a particularly promising in vitro system. RESULTS: We show, here, the antitumour potential of a bispecific antibody, BiUII, in three-dimensional multicellular tumour spheroids and furthermore demonstrate that BiUII triggers peripheral blood mononuclear cells to invade MTSs and elicit the production of TNFalpha, resulting in the efficient destruction of tumour cells. CONCLUSION: These results demonstrate that bispecific antibodies are capable of activating immune effector cells, resulting in the elimination of three-dimensional structures of tumour cells. The therapeutic potential of these antibodies in the clinical setting merits further investigations.


Subject(s)
Antibodies, Bispecific/pharmacology , Carcinoma, Squamous Cell/therapy , Head and Neck Neoplasms/therapy , Immunization, Passive/methods , Antibodies, Bispecific/immunology , Antibodies, Bispecific/pharmacokinetics , Antigens, Neoplasm/biosynthesis , Antigens, Neoplasm/immunology , Carcinoma, Squamous Cell/immunology , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/pathology , Cell Adhesion Molecules/biosynthesis , Cell Adhesion Molecules/immunology , Epithelial Cell Adhesion Molecule , Head and Neck Neoplasms/immunology , Head and Neck Neoplasms/metabolism , Head and Neck Neoplasms/pathology , Humans , Leukocytes, Mononuclear/immunology , Spheroids, Cellular , Tumor Cells, Cultured
11.
Cancer Genomics Proteomics ; 1(2): 167-176, 2004.
Article in English | MEDLINE | ID: mdl-31394681

ABSTRACT

BACKGROUND: Tumor cells have developed several strategies to escape the immune system. One of these strategies consists of the secretion of immunosuppressive factors like interleukin-10 or prostaglandin E2 (PGE2), which impair the immune system. We have demonstrated recently that tumor-derived PGE2 down-regulates the expression of the integrin Mac-1 and the chemokine receptor CCR5 on primary monocytes, resulting in reduced adhesion and migration. MATERIALS AND METHODS: In order to identify new target genes for tumor-derived factors in monocytes, we set up an in vitro system consisting of cDNA micro arrays and 2D gel electrophoresis. RESULTS: We identified 25 genes that were differentially expressed upon incubation of cells in conditioned tumor cell supernatants as compared to cells incubated in cell culture medium. We describe in more detail that IL-1ß secretion is induced by tumor supernatants and that IL-1ß overexpression is also evident in monocytes from tumor patients in vivo, where expression correlates with the tumor stage. In addition, up-regulation of the plasminogen activator inhibitor-2, PAI-2, and down-regulation of the urokinase-type plasminogen activator receptor, uPAR, resulted in a reduced capability of monocytes to degrade and invade extracellular matrices. CONCLUSION: In summary, we describe interesting novel targets of soluble tumor-derived factors that are probably involved in the tumor-mediated immunosuppression commonly found in cancer patients.

12.
FASEB J ; 17(2): 286-8, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12490541

ABSTRACT

Epidemiological data and animal models have provided evidence that nonsteroidal antiinflammatory drugs (NSAIDs) have an anticancer effect. However, the molecular mechanisms underlying these antineoplastic effects are not well understood. We described previously that expression levels of the chemokine receptor, CCR5, and the beta2-integrin, Mac-1, were down-regulated on primary monocytes after incubation in supernatants from human carcinoma cell lines, and that this down-regulation resulted in impaired monocyte function with respect to migration and adhesion. We now demonstrate that these impairments are also present in vivo. Monocytes from cancer patients displayed significantly reduced CCR5 levels and migration capacities in comparison to cells from healthy donors. Because migration is necessary for the antitumor activity of monocytes/macrophages, these deficits may contribute to the suppressed immune system seen in cancer patients. In a clinical study, we analyzed the effect of a selective COX-2 inhibitor, Rofecoxib, on the migration of monocytes derived from cancer patients. The results revealed significant improvement in migration equal to those levels seen in healthy donors. We conclude that in patients with cancer, the intake of Rofecoxib for 3 wk leads to significant restoration of monocyte function. These data may, at least in part, help explain the anticancer effects of NSAIDs.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Carcinoma, Squamous Cell/blood , Cyclooxygenase Inhibitors/pharmacology , Head and Neck Neoplasms/blood , Monocytes/drug effects , Aspirin/pharmacology , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/pathology , Cell Movement/drug effects , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/pathology , Indomethacin/pharmacology , Lactones/pharmacology , Monocytes/physiology , Prostaglandin-Endoperoxide Synthases/drug effects , Prostaglandin-Endoperoxide Synthases/metabolism , Receptors, CCR5/drug effects , Receptors, CCR5/metabolism , Sulfones
SELECTION OF CITATIONS
SEARCH DETAIL
...